Skip to Content

'
Alma Rodriguez

Present Title & Affiliation

Primary Appointment

Internist and Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Vice President of Medical Affairs, Division of Ofc/EVP, Physician-in-Chief, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2010

Education & Training

Degree-Granting Education

1979 University of Texas Medical School at Houston, Houston, TX, MD, AOA
1975 Our Lady of the Lake College, San Antonio, TX, BA, Chemistry and Biology, Graduate with Highest Honors

Board Certifications

1986 American Board of Medical Oncology
1982 American Board of Internal Medicine

Experience/Service

Institutional Committee Activities

Member, President's Advisory Committee, 9/2005-present
Member, Project Bed Task Force, 9/2005-present
Member, Cancer Prevention Clinic Advisory Board, 9/2005-present
Ex-officio, Clinical Effectiveness Committee, 4/2005-present
Member, Intensive Care Unit Subcommittee, 4/2005-present
Member, Sedation and Procedures Subcommittee, 4/2005-present
Ex-officio, Credential Committee of the Medical Staff, 7/2004-present
Ex-officio, Executive Committee of the Medical Staff, 7/2004-present
Member, Council of Committee Chairs, 7/2004-present
Member, Professional Liability Committee, 7/2004-present
Member, Clinical Council, 7/2004-present
Member, Advisory Group to the Assoc. Vice President for Clinical and Translational Research, 1/1995-present

Honors and Awards

2007-2008 Best Doctors in America
2007 Fellow, Clinical Safety & Effectiveness (CS&E)
2001 Fellow, American College of Physicians

Professional Memberships

American Association for Cancer Research (AACR)
Member, 1994-present
American College of Medical Quality (ACMQ)
Member, 2006-present
American College of Physicians-American Society of Internal Medicine (ACP/ASIM)
Member, 1997-present
American Medical Association (AMA)
Member, 1992-present
American Society of Clinical Oncology (ASCO)
Member, 1986-present
American Society of Hematology (ASH)
Member, 1993-present
Southwest Oncology Group (SWOG)
Member, 2006-present
Texas Medical Association and Harris County Medical Society
Member, 1987-present
Texas Society of Medical Oncology (TSMO)
Member, 1989-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Younes A, Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez A, Samaniego F, McLaughlin PW, Hagemeister FB, Neelapu SS, Copeland AR, Samuels BI, Loyer EM, Ji Y. Phase II Study of Yttrium-90 (90Y)-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. In Press.
2. Rodriguez MA, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN. Vincristine Sulfate Liposomes Injection (Marqibo) in Heavily Pretreated Patients with Refractory Aggressive non-Hodgkin Lymphoma: Report of the Pivotal Phase 2 Study. Cancer 115(15):3475-3482, 8/2009. PMID: 19536896.
3. Rodriguez MA, Storm CD, Burris, III HA. Medical Errors: Physician and Institutional Responsibilities. Journal of Oncology Practice 5(1), 1/2009.
4. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 11/2008. PMID: 18973182.
5. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Combination with Rituximab in Patients with Recurrent B-cell Non-Hodgkin Lymphoma. British Journal of Haematology, 11/2008. e-Pub 9/2008.
6. Russell NC, Hoelscher DM, Janszen L, Rodriguez MA. Dietary and weight changes after treatments for lymphoma. Nutr Cancer 57(2):168-76, 2007. PMID: 17571950.
7. Liu Q, Fayad L, Cabanillas F, Hagemeister F, Ayers G, hess M, Romaguera R, Rodriguez A, Tsimberidou A, Verstovsek S, Younes A, Pro B, Lee M, Ayala A, McLaughlin P. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 years of Treatment Experience at The University of Texas M. D. Anderson Cancer Center. J. Clin. Oncol 24, No. 10:1582-1589, 4/2006.
8. Rodriguez A. fter Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma with Rituximab plus hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. J. Clin. Oncol. 23(28:188-193, 10/2005.
9. Rodriguez A. Reduced-intensity Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen. Bone Marrow Transplantation 35(10):943-51, 5/2005.
10. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22:4095-102, 10/2004. PMID: 15353540.
11. Cohen L, Warneke C, Fouladi RT, Rodriguez MA. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer 100(10):2253-2260, 2004.
12. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98:310-4, 7/2003. PMID: 12872350.
13. Lee HK, Wilder RB, Jones D, Ha CS, Pro B, Rodriguez MA, Romaguera JE, Cabanillas F, Rodriguez J, Cox JD. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 43:1769-75, 9/2002. PMID: 12685830.
14. Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 94:3083-8, 6/2002. PMID: 12115338.
15. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91(12):2440-6, 6/2001. PMID: 11413536.
16. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 11(12):1551-6, 12/2000. PMID: 11205462.
17. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93(7):2202-7, 4/1999. PMID: 10090928.
18. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91(4):1178-84, 2/1998. PMID: 9454747.
19. Rodriguez MA. Factors that influence prognosis of intermediate-grade lymphomas at relapse. Cancer Treat Res 85:79-86, 1996. PMID: 9043776.
20. McLaughlin P, Hagemeister FB, Swan F, Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-9, 3/1994. PMID: 8120556.
21. Woo SY, Fuller LM, Cundiff JH, Bondy ML, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Jr, Rodriguez MA, Cabanillas F, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys 23:407-12, 1992. PMID: 1587764.
22. Rodriguez MA, Tortorella F, St. John C. Improving Psychosocial Care for Improved Health Outcomes. Journal of Healthcare Quality. Submitted.

Abstracts
1. Habra MA, Thompson MA, Rodriguez MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG: Primary Natural Killer/T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of a Rare Disorder. Primary Natural Killer/T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of a Rare Disorder. The Endocrine Society's 87th Annual Meeting 87th Annual Meeting, 2005.

Manuals, Teaching Aids, Other Teaching Publications
1. Polansky M, Rodriguez MA. Introduction to Clinical Oncology e-Course for Nursing, 2/2009.
 

Other
1. Participant in video: Cancer Survivorship Program.

Last updated: 9/25/2009